Fig. 4
Anti-PD-1 antibody enhances the efficacy of DNT cell-mediated inhibition of late-stage tumor growth. NSG mice were inoculated subcutaneously with NCI-H460 in 50% Matrigel solution and grown to ~100mm3. After tumors were established, tumor bearing mice were randomized and received peritumoral injection of DNT cells and IL-2 on day 0, 3 and 6, without or with anti-PD-1 antibody (10 mg/kg repeated every 5 days i.p., starting one day prior to 1st DNT cell infusion). a Schematic diagram of the treatment protocol of NCI-H460 xenograft model. b Tumor volume was measured at indicated time points (n = 8 for each group). c Survival of the mice treated with PBS control or DNT cells with or without anti-PD-1 (n = 8 for each group). d. Representative h&e staining of xenografts from indicated treatment groups 9-days post DNT cell infusion (n = 6 for each group; 3 tumors each with 2 random sections). e Percent necrotic area in tumors from indicated treatment groups calculated by histological analysis (n = 6 for each group; 3 tumors each with 2 random sections). Representative results shown as mean and SEM of 2 separate experiments. *p < 0.05, **p < 0.01, ***p < 0.001, by two-tailed unpaired t test (b), log-rank test (c), or one-way ANOVA (e)